Informed decisions. Stronger start-up.
Build an evidence-based strategy for countries, sites and enrollment
GET THE CASE STUDY: Integrated Feasibility Assessment Fast-Tracks a Biotech Rare Disease Study
What does it take to turn a complex rare disease study into an executable Phase 3 start-up plan? For one biotech sponsor, it meant looking beyond country-level potential to understand what geographies and sites truly support the protocol, patient population and enrollment timeline.
Read the case study to see how IQVIA expertly brought feasibility and site identification together to help a biotech sponsor navigate uncertainty and move forward with confidence in a challenging rare disease landscape.
Fill out the form to access the case study.
